First choice, second thoughts: low persistence with MS therapies


REPORT FROM THE 25TH CONGRESS OF THE EUROPEAN COMMITTEE  FOR TREATMENT AND RESEARCH IN MULTIPLE SCLEROSIS (ECTRIMS) – AMSTERDAM, THE NETHERLANDS, OCTOBER 19-22, 2011 – MS patients receiving a disease-modifying therapy (DMT) typically stop treatment or switch medications within a few years of starting treatment, according to a new database analysis of MS patients in British Columbia, Canada (Evans et al. ECTRIMS 2011; abstract P687).

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page